Haemonetics Announces CE Mark Certification for the VASCADE MVP® XL Venous Vascular Closure System
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Haemonetics (NYSE: HAE) received CE Mark certification for its VASCADE MVP XL venous vascular closure system under the European Medical Device Regulation.
The certification covers closure of femoral vein access sites after catheter-based procedures using sheaths with a 10–12F inner diameter and a maximum 15F outer diameter. It covers single or multiple access sites in one or both limbs and enables Haemonetics to offer the device in the EU and other markets that recognize CE marking. The first commercial European procedures took place in October in Germany, Italy and the UK.
Positive
- Minor pointCE Mark certification for VASCADE MVP XL enables sales in the EU and other markets that recognize CE marking.
- Minor pointFirst commercial European procedures with VASCADE MVP XL were completed in October in Germany, Italy and the UK.
Negative
- None.
Key Figures
- Collagen increase
- 58% more
- VASCADE MVP XL vs. VASCADE MVP
- Disc size increase
- 9% larger
- VASCADE MVP XL vs. VASCADE MVP
- Procedural sheath inner diameter
- 10–12F
- VASCADE MVP XL indicated procedures
- Maximum sheath outer diameter
- 15F
- VASCADE MVP XL indicated procedures
Key Terms
eu-mdr regulatory
hemostasis medical
percutaneous medical
pulsed field ablation (pfa) medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
First Commercial European Procedures Completed in
VASCADE MVP XL is CE marked under the EU-MDR (European Medical Device Regulation) for the percutaneous closure of femoral venous access sites while reducing time to ambulation, total post-procedure time, time to hemostasis and time to discharge eligibility compared to conventional closure methods, and enabling same-day discharge in patients who have undergone catheter-based procedures using 10–12F inner diameter (15F maximum outer diameter) procedural sheaths, with single or multiple access sites in one or both limbs. Using
"VASCADE MVP XL has driven the growth of our Interventional Technologies business in
"The VASCADE MVP system has become an important part of our approach to post-procedure care, helping us shorten time to ambulation and facilitate earlier discharge for appropriate patients," said Prof. Dr. Christian H. Heeger, Director Department of Rhythmology at Asklepios Clinic Altona in
In addition to the VASCADE MVP XL system, Haemonetics' vascular closure portfolio includes the VASCADE® vascular closure system, designed for "small-bore" femoral arterial and venous closure with standard 5-6/7F procedural sheaths, and the VASCADE MVP system, designed for "mid-bore" multi-access femoral venous closure with 6-12F ID procedural sheaths. Both closure devices are CE marked under the EU-MDR for use in patients who have undergone catheter-based procedures and include proprietary collapsible disc technology and a resorbable collagen plug to achieve hemostasis.
ABOUT HAEMONETICS
Haemonetics is a global medical technology company dedicated to improving the quality, effectiveness, and efficiency of health care. Our Apheresis business features proprietary technologies designed to enhance safety, yield, donor satisfaction and operational efficiency for plasma and blood collectors around the world. Our MedSurg business offers Blood Management Technologies to help inform treatment decisions and optimize the management of blood products, and Interventional Technologies, including advanced vascular closure systems and sensor-guided technologies, designed to drive procedural effectiveness and elevate the patient experience. To learn more about Haemonetics, visit www.haemonetics.com.
Cautionary Statement Regarding Forward-Looking Information
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements in this press release may include, without limitation, statements regarding plans and objectives of management for the operation of Haemonetics, including statements regarding potential benefits associated with the VASCADE MVP XL venous vascular closure system and Haemonetics' plans or objectives related to the commercialization of such product. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon Haemonetics' current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, product quality; market acceptance; the effect of economic and political conditions; and the impact of competitive products and pricing. These and other factors are identified and described in more detail in Haemonetics' periodic reports and other filings with the U.S. Securities and Exchange Commission. Haemonetics does not undertake to update these forward-looking statements.
|
Investor Contacts: |
|
|
|
Olga Guyette, Vice President-Investor Relations & Treasury |
David Trenk, Sr. Manager-Investor Relations |
|
|
(781) 356-9763 |
(203) 733-4987 |
|
|
|
|
|
|
Media Contact: |
|
|
|
Josh Gitelson, Sr. Director-Global Communications |
||
|
(781) 356-9776 |
|
|

View original content to download multimedia:https://www.prnewswire.com/news-releases/haemonetics-announces-ce-mark-certification-for-the-vascade-mvp-xl-venous-vascular-closure-system-302942972.html
SOURCE Haemonetics Corporation
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What use does Haemonetics’ VASCADE MVP XL CE Mark certification cover?
The certification covers closure of femoral vein access sites after catheter-based procedures using sheaths with a 10–12F inner diameter and a maximum 15F outer diameter. It applies to single or multiple access sites in one or both limbs.
Where did Haemonetics’ first commercial European procedures with VASCADE MVP XL take place?
The first procedures took place in October at Asklepios Clinic Altona in Hamburg, Germany; Centro Cardiologico Monzino, IRCCS in Milan, Italy; and Cromwell Hospital in London, UK.